Bendamustine treatment for Multiple Myeloma

  • facebook-icon
  • twitter-icon
  • linkedin-icon
  • reddit-icon

Bendamustine treatment for Multiple Myeloma

Bendamustine is used as an effective fir-line treatment for heavily pre-treated relapsed patients and multiple myeloma (MM) patients. The combination therapy of Treanda (generic Bendamustine) with other drugs like Rituximab are considered when all the other treatment options have been exhausted.

Who is at risk for developing Multiple Myeloma

Bendamustine rituximab treatment is very effective in treatment of multiple myeloma. Multiple myeloma is a plasma cell neoplasm which is categorised by the build-up of clonal bone marrow plasma cells that produces an abnormal monoclonal immunoglobin which can be detected in either urine or blood. Multiple myeloma is held responsible for almost 10% of all hematologic malignancies.

Since the approval of Treanda (generic Bendamustine) in 2011, this drug has proved to be very viable treatment option for the patients who are suffering with refractory or relapsed multiple myeloma.

Bendamustine cost information

Bendamustine Mechanism of Action

A bi-functional alkylating agent with structural resemblances to both purine analogues and alkylating agents, bendamustine induces anti-tumor effects by causing inter- and intra-strand cross-links between DNA bases that are more extensive and durable than those caused by other alkylating agents. Thus, bendamustine displays incomplete cross-resistance with melphalan and cyclophosphamide.

Patient characteristics

During a recent study conducted in Korea between November 2011 and September 2013, a total of 65 patients were selected at random who would receive bendamustine treatment. There were 36 patients who were diagnosed with multiple myeloma who underwent ASCT after induction treatment. The median for previous treatments was 5 year and median for bendamustine treatment was 3.8 years. And as a result, the median age was 63 years for the first time of bendamustine treatment. And a substantial number of patients who received bendamustine treatment had a advanced disease with bone marrow function and impairment of renal.

Bendamustine side effects

Some common side effects of using Treanda (generic bendamustine) were –

• joint pain, stiffness, or swelling
• Black, tarry stools
• chest pain
• bleeding gums
• blood in the urine or stools
• chills
• cough or hoarseness
• diarrhea
• fever
• headache
• lack or loss of strength
• lower back, side, or stomach pain
• sore throat
• muscle aches
• nausea
• painful or difficult urination
• pale skin
• pinpoint red spots on the skin
• ulcers, sores, or white spots in the mouth
• stuffy or runny nose
• swelling of the feet or lower legs
• swollen glands
• troubled breathing with exertion
• unusual bleeding or bruising
• unusual tiredness or weakness
• vomiting

The above side effects were also faced by the patients were enrolled in the study.

Survival outcome

The median of Overall survival was 5.5 months and Progression free survival after the bendamustine treatment was 3.1 months. Although the median was very short, but there were a total of 14 patients who lived longer than 12 months after starting with bendamustine treatment. The overall survival in recruited patients who responded with bendamustine was significantly higher than those who didn't respond to the treatment.

The performance status of the patients was significantly linked to the Overall Survival and improved Overall survival was also observed among the patients who were less than 60 years. However, the median treatments lines prior to the treatment with bendamustine was not all linked to overall survival.

Bendamustine / Treanda cost information

The information provided on the page is meant for the purpose of being helpful and educational. It should not be considered as medical advice. bendamustine, treanda, bendamustine side effects, bendamustine rituximab, bendamustine cost, bendamustine mechanism of action, treanda cost, bendamustine hydrochloride, treanda side effects

Leave a Comment
All fields are mandatory *
captcha
TOP